作者
Natalie E LeCouffe, Manon Kappelhof, Kilian M Treurniet, Leon A Rinkel, Agnetha E Bruggeman, Olvert A Berkhemer, Lennard Wolff, Henk van Voorst, Manon L Tolhuisen, Diederik WJ Dippel, Aad van der Lugt, Adriaan CGM van Es, Jelis Boiten, Geert J Lycklama à Nijeholt, Koos Keizer, Rob AR Gons, Lonneke SF Yo, Robert J van Oostenbrugge, Wim H van Zwam, Bob Roozenbeek, H Bart van der Worp, Rob TH Lo, Ido R van den Wijngaard, Inger R de Ridder, Vincent Costalat, Caroline Arquizan, Robin Lemmens, Jelle Demeestere, Jeannette Hofmeijer, Jasper M Martens, Wouter J Schonewille, Jan-Albert Vos, Maarten Uyttenboogaart, Reinoud PH Bokkers, Julia H van Tuijl, Hans Kortman, Floris HBM Schreuder, Hieronymus D Boogaarts, Karlijn F de Laat, Lukas C van Dijk, Heleen M den Hertog, Boudewijn AAM van Hasselt, Paul JAM Brouwers, Tomas Bulut, Michel JM Remmers, Anouk van Norden, Farshad Imani, Anouk D Rozeman, Otto EH Elgersma, Philippe Desfontaines, Denis Brisbois, Yves Samson, Frédéric Clarençon, G Menno Krietemeijer, Alida A Postma, Pieter-Jan van Doormaal, René van den Berg, Anouk van der Hoorn, Ludo FM Beenen, Daan Nieboer, Hester F Lingsma, Bart J Emmer, Jonathan M Coutinho, Charles BLM Majoie, Yvo BWEM Roos
发表日期
2021/11/11
期刊
New England journal of medicine
卷号
385
期号
20
页码范围
1833-1844
出版商
Massachusetts Medical Society
简介
Background
The value of administering intravenous alteplase before endovascular treatment (EVT) for acute ischemic stroke has not been studied extensively, particularly in non-Asian populations.
Methods
We performed an open-label, multicenter, randomized trial in Europe involving patients with stroke who presented directly to a hospital that was capable of providing EVT and who were eligible for intravenous alteplase and EVT. Patients were randomly assigned in a 1:1 ratio to receive EVT alone or intravenous alteplase followed by EVT (the standard of care). The primary end point was functional outcome on the modified Rankin scale (range, 0 [no disability] to 6 [death]) at 90 days. We assessed the superiority of EVT alone over alteplase plus EVT, as well as noninferiority by a margin of 0.8 for the lower boundary of the 95% confidence interval for the odds ratio of the two trial groups. Death from any cause …
学术搜索中的文章
NE LeCouffe, M Kappelhof, KM Treurniet, LA Rinkel… - New England journal of medicine, 2021